Clinical Bioenergetics: From Pathophysiology to Clinical Translation provides recent developments surrounding the etiology and pathophysiology of inherited and acquired energy-delated disorders. Across 40 chapters, world leaders in bioenergetics and mitochondrial medicine discuss novel methodologies designed to identify deficiencies in cellular bioenergetics, as well as the safety and efficacy of emerging management strategies to address poor cellular bioenergetics. Topics discussed include the omics landscape of impaired mitochondrial bioenergetics, hormones, tissue bioenergetics and metabolism in humans. Disease-specific case studies, modes of analysis in clinical bioenergetics, and therapeutic opportunities for impaired bioenergetics, addressing both known treatment pathways and future directions for research, are discussed in-depth.
Diseases and Disorders examined include brain injury, chronic fatigue syndrome, psychiatric disorders, pulmonary fibrosis, neurodegenerative disorders, heart failure, chronic kidney disease, obesity, and insulin resistance, among others.
1. Introduction - p. 3 2. Energetic metabolic profile of tissues and cell types - p. 7 3. Mitochondrial heterogeneity and tissue-specific properties of mitochondria - p. 17 4. Regulation of mitochondrial biogenesis and degradation - p. 29 5. Conclusions and perspectives - p. 39 6. Chapter 2. Impaired mitochondrial bioenergetics and signaling pathways: an overview - p. 61 7. Part II. Disease-specific case studies - p. 79 8. Chapter 3. Abnormal mitochondrial metabolism in obesity and insulin resistance - p. 83 9. Chapter 4. Impaired mitochondrial energy metabolism: etiologies and implications in neurodegenerative disease - p. 93 10. Chapter 5. Mitochondrial dysfunction in kidney diseases - p. 119 11. Chapter 6. Mitochondrial role in NAFLD as a chronic disease - p. 155 12. Chapter 7. Decreased bioenergetics in traumatic brain injury - p. 169 13. Chapter 8. Impaired mitochondrial bioenergetics in psychiatric disorders - p. 195 14. Part III. Modes of analysis in clinical bioenergetics - p. 221 15. Chapter 9. Monitoring mitochondrial oxygenation in clinical environment - p. 225 16. Chapter 10. Assessing metabolic flexibility and mitochondrial bioenergetics - p. 245 17. Chapter 11. Assessing the real-time metabolism and bioenergetics of single cells using fluorescence biosensors - p. 269 18. Chapter 12. Bioenergetic profiling in the skin - p. 285 19. Chapter 13. Evaluating tissue bioenergetics by phosphorous-31 magnetic resonance spectroscopy - p. 309 20. Chapter 14. Targeting respiratory complex I—molecular mechanism and drug design - p. 327 21. Part IV. Theraputic opportunities for impaired bioenergetics - p. 340 22. Chapter 15. Targeting Alzheimer's disease neuronal mitochondria as a therapeutic approach - p. 343 23. Chapter 16. Mitochondria replacement as an innovative treatment to tackle impaired bioenergetics in clinical medicine - p. 365 24. Chapter 17. Mitochondrial drug delivery systems: therapeutic application for clinical bioenergetics in neurodegenerative disease - p. 385 25. Chapter 18. Dietary interventions for patients with obesity and impaired bioenergetics - p. 411 26. Chapter 19. Novel nutraceuticals to tackle brain and muscle bioenergetics - p. 431 27. Chapter 20. Therapeutic targeting of cardiolipin composition in injury and disease using TPP-conjugated compounds - p. 451 28. Chapter 21. NEET proteins as novel drug targets for mitochondrial dysfunction - p. 477 29. Chapter 22. Translation of bioenergetics therapies: challenges from bench to bedside - p. 489 30. Chapter 23. New therapeutics to modulate mitochondrial energy metabolism in neurodegenerative disorders: the example of mitochondrial disorders - p. 509 31. Chapter 24. Targeting impaired bioenergetics in heart failure - p. 533 32. Chapter 25. Exploring vulnerabilities of quiescent tumor cells by targeting mitochondrial bioenergetics - p. 547 33. Chapter 26. Modulation of the mitochondrial function with polyphenols and other natural bioactive compounds to treat obesity - p. 565 34. Chapter 27. Antioxidants and natural-derived products in the modulation of mitochondrial bioenergetics and dysfunction in chronic kidney disease models - p. 611 35. Chapter 28. Transcranial and systemic photobiomodulation for the enhancement of mitochondrial metabolism in depression - p. 635 36. Chapter 29. Alterations in mitochondrial glucose carbon metabolism in epilepsy and targeted metabolic treatments - p. 653 37. Index - p. 679
Clinical Bioenergetics: From Pathophysiology to Clinical Translation provides recent developments surrounding the etiology and pathophysiology of inherited and acquired energy-delated disorders. Across 40 chapters, world leaders in bioenergetics and mitochondrial medicine discuss novel methodologies designed to identify deficiencies in cellular bioenergetics, as well as the safety and efficacy of emerging management strategies to address poor cellular bioenergetics. Topics discussed include the omics landscape of impaired mitochondrial bioenergetics, hormones, tissue bioenergetics and metabolism in humans. Disease-specific case studies, modes of analysis in clinical bioenergetics, and therapeutic opportunities for impaired bioenergetics, addressing both known treatment pathways and future directions for research, are discussed in-depth.
Diseases and Disorders examined include brain injury, chronic fatigue syndrome, psychiatric disorders, pulmonary fibrosis, neurodegenerative disorders, heart failure, chronic kidney disease, obesity, and insulin resistance, among others.
1. Introduction - p. 3 2. Energetic metabolic profile of tissues and cell types - p. 7 3. Mitochondrial heterogeneity and tissue-specific properties of mitochondria - p. 17 4. Regulation of mitochondrial biogenesis and degradation - p. 29 5. Conclusions and perspectives - p. 39 6. Chapter 2. Impaired mitochondrial bioenergetics and signaling pathways: an overview - p. 61 7. Part II. Disease-specific case studies - p. 79 8. Chapter 3. Abnormal mitochondrial metabolism in obesity and insulin resistance - p. 83 9. Chapter 4. Impaired mitochondrial energy metabolism: etiologies and implications in neurodegenerative disease - p. 93 10. Chapter 5. Mitochondrial dysfunction in kidney diseases - p. 119 11. Chapter 6. Mitochondrial role in NAFLD as a chronic disease - p. 155 12. Chapter 7. Decreased bioenergetics in traumatic brain injury - p. 169 13. Chapter 8. Impaired mitochondrial bioenergetics in psychiatric disorders - p. 195 14. Part III. Modes of analysis in clinical bioenergetics - p. 221 15. Chapter 9. Monitoring mitochondrial oxygenation in clinical environment - p. 225 16. Chapter 10. Assessing metabolic flexibility and mitochondrial bioenergetics - p. 245 17. Chapter 11. Assessing the real-time metabolism and bioenergetics of single cells using fluorescence biosensors - p. 269 18. Chapter 12. Bioenergetic profiling in the skin - p. 285 19. Chapter 13. Evaluating tissue bioenergetics by phosphorous-31 magnetic resonance spectroscopy - p. 309 20. Chapter 14. Targeting respiratory complex I—molecular mechanism and drug design - p. 327 21. Part IV. Theraputic opportunities for impaired bioenergetics - p. 340 22. Chapter 15. Targeting Alzheimer's disease neuronal mitochondria as a therapeutic approach - p. 343 23. Chapter 16. Mitochondria replacement as an innovative treatment to tackle impaired bioenergetics in clinical medicine - p. 365 24. Chapter 17. Mitochondrial drug delivery systems: therapeutic application for clinical bioenergetics in neurodegenerative disease - p. 385 25. Chapter 18. Dietary interventions for patients with obesity and impaired bioenergetics - p. 411 26. Chapter 19. Novel nutraceuticals to tackle brain and muscle bioenergetics - p. 431 27. Chapter 20. Therapeutic targeting of cardiolipin composition in injury and disease using TPP-conjugated compounds - p. 451 28. Chapter 21. NEET proteins as novel drug targets for mitochondrial dysfunction - p. 477 29. Chapter 22. Translation of bioenergetics therapies: challenges from bench to bedside - p. 489 30. Chapter 23. New therapeutics to modulate mitochondrial energy metabolism in neurodegenerative disorders: the example of mitochondrial disorders - p. 509 31. Chapter 24. Targeting impaired bioenergetics in heart failure - p. 533 32. Chapter 25. Exploring vulnerabilities of quiescent tumor cells by targeting mitochondrial bioenergetics - p. 547 33. Chapter 26. Modulation of the mitochondrial function with polyphenols and other natural bioactive compounds to treat obesity - p. 565 34. Chapter 27. Antioxidants and natural-derived products in the modulation of mitochondrial bioenergetics and dysfunction in chronic kidney disease models - p. 611 35. Chapter 28. Transcranial and systemic photobiomodulation for the enhancement of mitochondrial metabolism in depression - p. 635 36. Chapter 29. Alterations in mitochondrial glucose carbon metabolism in epilepsy and targeted metabolic treatments - p. 653 37. Index - p. 679
